Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2013

01.09.2013 | short review

Cancer-associated venous thromboembolism: risk assessment, prevention, and treatment

verfasst von: Clemens Feistritzer, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

The association between cancer and the development of venous thromboembolism is well documented. Cancer-related venous thromboembolism is associated with worsened short-term as well as long-term survival—it also affects the quality of life of the patient and may delay ongoing treatment. Interaction of cancer cells as well as effects of chemotherapy can lead to a systematic activation of coagulation system. Consequently, venous thromboembolism in cancer patients has been associated with several tumor-, treatment- and patient- related risk factors. Several studies focused on possibilities to predict the risk of venous thromboembolism in cancer patients. However, patient selection for prophylactic antithrombotic treatment remains a matter of controversy. In contrast, treatment of cancer-associated venous thromboembolism using low molecular weight heparin is well established. The role of the novel anticoagulants—new oral factor Xa and thrombin inhibitors in the treatment of cancer patients with venous thromboembolism remains to be determined. In this review, recently published studies and guidelines regarding risk assessment, prevention, and treatment of cancer-associated venous thromboembolism are summarized.
Literatur
1.
Zurück zum Zitat Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–50.PubMedCrossRef Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–50.PubMedCrossRef
2.
Zurück zum Zitat Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–34.PubMedCrossRef Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–34.PubMedCrossRef
3.
Zurück zum Zitat Khorana AA. Cancer-associated thrombosis: updates and controversies. Hematology Am Soc Hematol Educ Program. 2012;2012:626–30.PubMed Khorana AA. Cancer-associated thrombosis: updates and controversies. Hematology Am Soc Hematol Educ Program. 2012;2012:626–30.PubMed
4.
Zurück zum Zitat den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol. 2011;29:2405–09.PubMedCrossRef den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol. 2011;29:2405–09.PubMedCrossRef
5.
Zurück zum Zitat Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11:56–70.PubMedCrossRef Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11:56–70.PubMedCrossRef
6.
Zurück zum Zitat Ay C, Pabinger I. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. Thromb Res. 2012;129 Suppl 1:S6–9.PubMedCrossRef Ay C, Pabinger I. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. Thromb Res. 2012;129 Suppl 1:S6–9.PubMedCrossRef
7.
Zurück zum Zitat Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–07.PubMedCrossRef Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–07.PubMedCrossRef
8.
Zurück zum Zitat Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377–82.PubMedCrossRef Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377–82.PubMedCrossRef
9.
Zurück zum Zitat Verso M, Agnelli G, Barni S, Gasparini G, Labianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7:291–92.PubMedCrossRef Verso M, Agnelli G, Barni S, Gasparini G, Labianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7:291–92.PubMedCrossRef
10.
Zurück zum Zitat Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366:601–09.PubMedCrossRef Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366:601–09.PubMedCrossRef
11.
Zurück zum Zitat George D, Agnelli G, Fisher W, et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118:206. George D, Agnelli G, Fisher W, et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118:206.
12.
Zurück zum Zitat Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793–800.PubMedCrossRef Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793–800.PubMedCrossRef
13.
Zurück zum Zitat Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–9.PubMedCrossRef Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–9.PubMedCrossRef
14.
Zurück zum Zitat Mandala M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22 Suppl 6:vi85–92.PubMedCrossRef Mandala M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22 Suppl 6:vi85–92.PubMedCrossRef
15.
Zurück zum Zitat Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th edn, In: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. vol. 141, Northbrook, Chest; 2012. pp e195S-226S. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th edn, In: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. vol. 141, Northbrook, Chest; 2012. pp e195S-226S.
16.
Zurück zum Zitat Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29:986–93.PubMedCrossRef Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29:986–93.PubMedCrossRef
17.
Zurück zum Zitat Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48:1283–92. Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48:1283–92.
18.
Zurück zum Zitat Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10:943–9.PubMedCrossRef Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10:943–9.PubMedCrossRef
19.
Zurück zum Zitat Akl EA, Gunukula S, Barba M, et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011CD006652. Akl EA, Gunukula S, Barba M, et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011CD006652.
20.
Zurück zum Zitat Akl EA, Vasireddi SR, Gunukula S, et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011CD006466. Akl EA, Vasireddi SR, Gunukula S, et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011CD006466.
21.
Zurück zum Zitat Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243:89–95.PubMedCrossRef Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243:89–95.PubMedCrossRef
22.
Zurück zum Zitat Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975–80.PubMedCrossRef Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975–80.PubMedCrossRef
23.
Zurück zum Zitat Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg. 1995;82:496–501.PubMedCrossRef Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg. 1995;82:496–501.PubMedCrossRef
24.
Zurück zum Zitat Akl EA, Terrenato I, Barba M, et al. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med. 2008;168:1261–69.PubMedCrossRef Akl EA, Terrenato I, Barba M, et al. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med. 2008;168:1261–69.PubMedCrossRef
25.
Zurück zum Zitat Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–53. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–53.
26.
Zurück zum Zitat Akl EA, Barba M, Rohilla S, et al. Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a Cochrane systematic review. J Exp Clin Cancer Res. 2008;27:21. Akl EA, Barba M, Rohilla S, et al. Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a Cochrane systematic review. J Exp Clin Cancer Res. 2008;27:21.
27.
Zurück zum Zitat Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189–2204.PubMedCrossRef Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189–2204.PubMedCrossRef
28.
Zurück zum Zitat Carrier M, Le GG, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7:760–5.PubMedCrossRef Carrier M, Le GG, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7:760–5.PubMedCrossRef
29.
Zurück zum Zitat Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52.PubMedCrossRef Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52.PubMedCrossRef
30.
Zurück zum Zitat Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–97.PubMedCrossRef Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–97.PubMedCrossRef
31.
Zurück zum Zitat Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708.PubMedCrossRef Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708.PubMedCrossRef
32.
Zurück zum Zitat Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10:807–14.PubMedCrossRef Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10:807–14.PubMedCrossRef
Metadaten
Titel
Cancer-associated venous thromboembolism: risk assessment, prevention, and treatment
verfasst von
Clemens Feistritzer, MD
Publikationsdatum
01.09.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0098-4

Weitere Artikel der Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013 Zur Ausgabe